Geron Corporation (GERN) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Geron Corporation stock (GERN) is currently trading at $1.57. Geron Corporation PS ratio (Price-to-Sales) is 5.09. Analyst consensus price target for GERN is $3.40. WallStSmart rates GERN as Sell.
- GERN PE ratio analysis and historical PE chart
- GERN PS ratio (Price-to-Sales) history and trend
- GERN intrinsic value — DCF, Graham Number, EPV models
- GERN stock price prediction 2025 2026 2027 2028 2029 2030
- GERN fair value vs current price
- GERN insider transactions and insider buying
- Is GERN undervalued or overvalued?
- Geron Corporation financial analysis — revenue, earnings, cash flow
- GERN Piotroski F-Score and Altman Z-Score
- GERN analyst price target and Smart Rating
Geron Corporation
📊 No data available
Try selecting a different time range
Smart Analysis
Geron Corporation (GERN) · 9 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in institutional own.. Concerns around peg ratio and return on equity. Significant fundamental concerns warrant caution or avoidance.
Geron Corporation (GERN) Key Strengths (1)
78.22% of shares held by major funds and institutions
Supporting Valuation Data
Geron Corporation (GERN) Areas to Watch (8)
PEG ratio is negative or unavailable
Company is destroying shareholder value
Losing money on operations
Company is losing money with a negative profit margin
Revenue growing slowly at 1.00% annually
Premium valuation at 5.1x annual revenue
Premium pricing at 4.1x book value
Small-cap company with higher risk but more growth potential
Supporting Valuation Data
Geron Corporation (GERN) Detailed Analysis Report
Overall Assessment
This company scores 23/100 in our Smart Analysis, earning a F grade. Out of 9 metrics analyzed, 1 register as strengths (avg 10.0/10) while 8 fall into concern territory (avg 1.9/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Institutional Own..
The Bear Case
The primary concerns are PEG Ratio, Return on Equity, Operating Margin. Some valuation metrics including PEG Ratio (N/A), Price/Sales (5.09), Price/Book (4.11) suggest expensive pricing. Growth concerns include Revenue Growth at 1.00%, which may limit upside. Profitability pressure is visible in Return on Equity at -33.00%, Operating Margin at -17.70%, Profit Margin at -45.40%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether PEG Ratio improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -33.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 1.00% needing to reaccelerate.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. PEG Ratio and Return on Equity are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
GERN Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
GERN's Price-to-Sales ratio of 5.09x trades at a deep discount to its historical average of 969.27x (0th percentile). The current valuation is 100% below its historical high of 3434.53x set in Aug 2018, and 0% above its historical low of 5.09x in Mar 2026. Over the past 12 months, the PS ratio has compressed from ~5.8x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Geron Corporation (GERN) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Geron Corporation is in a turnaround phase, with management focused on restoring profitability. Revenue reached 184M with 1% growth year-over-year. The company is currently unprofitable, posting a -45.4% profit margin.
Key Findings
The company is unprofitable with a -45.4% profit margin. The path to breakeven will be the key catalyst.
Free cash flow is -22M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Geron Corporation.
Bottom Line
Geron Corporation is in turnaround mode. The path to profitability remains the critical question. Speculative investors may see opportunity in the recovery story, but conservative investors should wait for consistent positive earnings before committing capital.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Geron Corporation(GERN)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The company is headquartered in Foster City, California.